Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The ...

Robert F. Kennedy, Jr., President Trump's nominee to serve as Secretary of Health and Human Services testifies during a ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...